Kiniksa Pharmaceuticals (KNSA) revenue breakdown
By product, Product revenue, net is the largest at 99% of fiscal 2024 revenue, growing 84% a year over 2 years.
By region, United States is the largest at 100% of fiscal 2025 revenue, growing 58% a year over 2 years.
Revenue by product
Fiscal years, as Kiniksa Pharmaceuticals reports them in its 10-K filings; fiscal 2024 total $423M.
| Products | 2022 | 2023 | 2024 | Share |
|---|---|---|---|---|
| Product revenue, net | $123M | $233M | $417M | 99% |
| License and collaboration revenue | $98M | $37M | $6M | 1% |
Revenue by region
Fiscal years, as Kiniksa Pharmaceuticals reports them in its 10-K filings; fiscal 2025 total $678M.
| Regions | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|
| United States | $270M | $421M | $677M | 100% |
| UK | $487,000 | $930,000 | $814,000 | 0% |
| Rest of world | — | $875,000 | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for KNSA.
Open KNSA in InvestinglyQuestions
Where does Kiniksa Pharmaceuticals make its money?
In fiscal 2024, by product: Product revenue, net $417M, License and collaboration revenue $6M.
From Kiniksa Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.